A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
JAK2 inhibitor monotherapy is effective in reducing splenomegaly and symptom burden in the majority of treated patients with myelofibrosis, but leukemic transformation can still occur.
Clinical Lymphoma, Myeloma & Leukemia
In The News
National Cancer Institute